European Commission approves Libtayo for advanced cutaneous squamous cell carcinoma

In The Headlines: Back to “business as usual” at FDA?

The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.

May 28, 2025

Vol.51 No.20

Regulatory News

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

May 23, 2025

Vol.51 No.20

By Jacquelyn Cobb

Clinical Trials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising.

May 23, 2025

Vol.51 No.20

By Peter Nelson

Clinical Trials & Tribulations

Unlocking the future of precision medicine:
The untapped power of RNA

True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanisms, and diagnosis that inform treatment.

May 23, 2025

Vol.51 No.20

By Eric Lefkofsky and Norman E. "Ned" Sharpless

Clinical

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

The American Society of Clinical Oncology and Google Cloud have developed a tool called the ASCO Guidelines Assistant to help oncologists parse through and interpret clinical practice guidelines.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand

As the leaders of the Public Affairs & Marketing Network set out to develop a strategic plan four years ago, they had to confront one surprising challenge.

May 23, 2025

Vol.51 No.20

By Jacquelyn Cobb

European Commission approves Libtayo for advanced cutaneous squamous cell carcinoma

YOU MAY BE INTERESTED IN

In The Headlines: Back to “business as usual” at FDA?

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unlocking the future of precision medicine:
The untapped power of RNA

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand

Renew today!

Subscriber content

Never miss an issue!

Login

European Commission approves Libtayo for advanced cutaneous squamous cell carcinoma

YOU MAY BE INTERESTED IN

In The Headlines: Back to “business as usual” at FDA?

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unlocking the future of precision medicine:The untapped power of RNA

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand

Never miss an issue!

Login

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unlocking the future of precision medicine:
The untapped power of RNA